LEADING THE SMALL MOLECULE FIGHT AGAINST RSV

Driving small molecule antiviral development for Respiratory Syncytial Virus infection

RSV: Serious Unmet Medical Need
  • RSV is a common and serious cause of respiratory infection in children, the immune-compromised and the elderly
  • The World Health Organization (WHO) estimates that RSV causes 64 million infections and 160,000 infant deaths each year
  • It is the most important respiratory virus, responsible for one-fifth of all lower respiratory tract infections worldwide
  • There are no effective treatments or vaccines available against RSV

Leading the Way: RV521

  • An RSV fusion (F) protein inhibitor
  • Best-in-class drug to treat RSV infections
  • Completed Phase 1 studies with antiviral exposures achieved
  • Completed RSV challenge model with high potency against both viral load and symptoms
  • Excellent safety profile
  • Entering an international multicentre Phase 2 paediatric trial
Meet the Team...
Dr Ken Powell

Dr Ken Powell

Chairman
Alex C. Sapir

Alex C. Sapir

Chief Executive Officer
Dr Eddy Littler

Dr Eddy Littler

Chief Operating Officer
Dr Stuart Cockerill

Dr Stuart Cockerill

Chief Scientific Officer, Founder
Dr Rachel Harland

Dr Rachel Harland

Head of Preclinical Development
Dr Neil Mathews

Dr Neil Mathews

Project Director, Founder
Max Herrmann

Max Herrmann

Chief Financial Officer
Dr Elaine Thomas

Dr Elaine Thomas

Head of Virology
Dr Seth Hetherington

Dr Seth Hetherington

Chief Medical Officer
Latest News
ReViral Appoints Alex C. Sapir as Chief Executive Officer
  • Proven leader with extensive corporate strategy experience in the biotechnology sector
  • Dr. Eddy Littler to remain as Chief Operating...
Read more...
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)

Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research...

Read more...
ReViral Announces Grant of Key US Composition of Matter Patent For Their Respiratory Syncytial Virus inhibitor programme

• Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended)
• The...

Read more...
Contact us...
Privacy Policy
© Reviral Ltd 2019